WO2011120474A9 - Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos - Google Patents
Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos Download PDFInfo
- Publication number
- WO2011120474A9 WO2011120474A9 PCT/CU2011/000001 CU2011000001W WO2011120474A9 WO 2011120474 A9 WO2011120474 A9 WO 2011120474A9 CU 2011000001 W CU2011000001 W CU 2011000001W WO 2011120474 A9 WO2011120474 A9 WO 2011120474A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytoskeleton
- human cells
- proteins
- virus
- mammal
- Prior art date
Links
- 210000005260 human cell Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000010076 replication Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 210000004292 cytoskeleton Anatomy 0.000 abstract 5
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 abstract 2
- 108010065038 Keratin-10 Proteins 0.000 abstract 2
- 102000013127 Vimentin Human genes 0.000 abstract 2
- 108010065472 Vimentin Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000003436 cytoskeletal effect Effects 0.000 abstract 1
- 210000003963 intermediate filament Anatomy 0.000 abstract 1
- -1 lipid compounds Chemical class 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 210000005048 vimentin Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012025092-2A BR112012025092B1 (pt) | 2010-04-01 | 2011-04-01 | Uso de um peptídeo capaz de romper os filamentos intermediários do citoesqueleto em uma célula de mamífero |
US13/637,845 US9205128B2 (en) | 2010-04-01 | 2011-04-01 | Method for inhibiting HIV replication in mammal and human cells |
EP11720370.3A EP2554550B1 (en) | 2010-04-01 | 2011-04-01 | Method for inhibiting hiv replication in mammal and human cells |
KR1020127028726A KR101869917B1 (ko) | 2010-04-01 | 2011-04-01 | 포유류와 인간 세포에서 hiv 복제를 억제하는 방법 |
MX2012011424A MX2012011424A (es) | 2010-04-01 | 2011-04-01 | Metodo para inhibir la repilacion del virus de la inmunodeficiencia humana en celulas de mamiferos y en humanos. |
RU2012146542/10A RU2593948C2 (ru) | 2010-04-01 | 2011-04-01 | Способ ингибирования репликации вич в клетках млекопитающих и у людей |
CN201180023063.3A CN102884075B (zh) | 2010-04-01 | 2011-04-01 | 用于抑制在哺乳动物细胞中和在人中的hiv复制的方法 |
JP2013501620A JP5925759B2 (ja) | 2010-04-01 | 2011-04-01 | 哺乳動物及びヒトの細胞においてhiv複製を阻害する方法 |
CA2794930A CA2794930C (en) | 2010-04-01 | 2011-04-01 | Method for inhibiting hiv replication in mammal and human cells |
ES11720370.3T ES2604702T3 (es) | 2010-04-01 | 2011-04-01 | Método para inhibir la replicación del VIH en células de mamíferos y humanos |
MYPI2012700711A MY161923A (en) | 2010-04-01 | 2011-04-01 | Method to inhibit hiv replication in mammal and human cells |
AU2011235369A AU2011235369B2 (en) | 2010-04-01 | 2011-04-01 | Method for inhibiting HIV replication in mammal and human cells |
ZA2012/07761A ZA201207761B (en) | 2010-04-01 | 2012-10-16 | Method for inhibiting hiv replication in mammal and human cells |
US14/943,106 US10434137B2 (en) | 2010-04-01 | 2015-11-17 | Method for inhibiting HIV replication in mammal and human cells |
US14/943,096 US20160106810A1 (en) | 2010-04-01 | 2015-11-17 | Method for Inhibiting HIV Replication in Mammal and Human Cells |
US14/943,089 US20160129073A1 (en) | 2010-04-01 | 2015-11-17 | Method for Inhibiting HIV Replication in Mammal and Human Cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2010-0056 | 2010-04-01 | ||
CU2010000056A CU23896B1 (es) | 2010-04-01 | 2010-04-01 | Método para inhibir la replicación del vih en células de mamíferos |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/637,845 A-371-Of-International US9205128B2 (en) | 2010-04-01 | 2011-04-01 | Method for inhibiting HIV replication in mammal and human cells |
US14/943,089 Continuation US20160129073A1 (en) | 2010-04-01 | 2015-11-17 | Method for Inhibiting HIV Replication in Mammal and Human Cells |
US14/943,106 Continuation US10434137B2 (en) | 2010-04-01 | 2015-11-17 | Method for inhibiting HIV replication in mammal and human cells |
US14/943,096 Continuation US20160106810A1 (en) | 2010-04-01 | 2015-11-17 | Method for Inhibiting HIV Replication in Mammal and Human Cells |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011120474A1 WO2011120474A1 (es) | 2011-10-06 |
WO2011120474A9 true WO2011120474A9 (es) | 2012-03-22 |
WO2011120474A8 WO2011120474A8 (es) | 2012-11-15 |
Family
ID=44168763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2011/000001 WO2011120474A1 (es) | 2010-04-01 | 2011-04-01 | Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos |
Country Status (16)
Country | Link |
---|---|
US (4) | US9205128B2 (es) |
EP (1) | EP2554550B1 (es) |
JP (2) | JP5925759B2 (es) |
KR (1) | KR101869917B1 (es) |
CN (1) | CN102884075B (es) |
AR (1) | AR080818A1 (es) |
AU (1) | AU2011235369B2 (es) |
BR (1) | BR112012025092B1 (es) |
CA (1) | CA2794930C (es) |
CU (1) | CU23896B1 (es) |
ES (1) | ES2604702T3 (es) |
MX (1) | MX2012011424A (es) |
MY (1) | MY161923A (es) |
RU (1) | RU2593948C2 (es) |
WO (1) | WO2011120474A1 (es) |
ZA (1) | ZA201207761B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102131041B1 (ko) | 2013-12-03 | 2020-07-08 | (주)아모레퍼시픽 | 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법 |
WO2015191874A1 (en) * | 2014-06-12 | 2015-12-17 | Children's National Medical Center | Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use |
WO2016200220A1 (ko) * | 2015-06-10 | 2016-12-15 | 주식회사 이뮨메드 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
WO2016199964A1 (ko) * | 2015-06-10 | 2016-12-15 | 주식회사 이뮨메드 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
CU20200110A7 (es) * | 2020-12-23 | 2022-08-09 | Ct Ingenieria Genetica Biotecnologia | Péptidos para el tratamiento de infecciones respiratorias de origen viral |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2128616A1 (en) | 1992-01-23 | 1993-08-05 | Gary H. Rhodes | Ex vivo gene transfer |
EP0915975A2 (en) | 1996-07-03 | 1999-05-19 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6476193B1 (en) * | 1998-10-06 | 2002-11-05 | Curagen Corporation | NLK1 protein and NLK1 protein complexes |
AU771546B2 (en) * | 1999-09-01 | 2004-03-25 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
KR100607611B1 (ko) * | 2000-08-24 | 2006-08-02 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
US20020160393A1 (en) | 2000-12-28 | 2002-10-31 | Symonds Geoffrey P. | Double-stranded RNA-mediated gene suppression |
JP2005521393A (ja) * | 2002-03-20 | 2005-07-21 | マサチューセッツ インスティテュート オブ テクノロジー | Hiv治療 |
US7691582B2 (en) * | 2002-09-27 | 2010-04-06 | The Regents Of The University Of Michigan | Methods of secretory vimentin detection and modulation |
TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
WO2006111866A2 (en) * | 2005-03-08 | 2006-10-26 | Molmed Spa | Hiv vif mutants |
US20090227518A1 (en) * | 2005-12-02 | 2009-09-10 | The Regents Of The University Of Colorado | Compositions and methods for treating actin-mediated medical conditions |
CU23674A1 (es) | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
-
2010
- 2010-04-01 CU CU2010000056A patent/CU23896B1/es active IP Right Grant
-
2011
- 2011-03-31 AR ARP110101094A patent/AR080818A1/es unknown
- 2011-04-01 WO PCT/CU2011/000001 patent/WO2011120474A1/es active Application Filing
- 2011-04-01 ES ES11720370.3T patent/ES2604702T3/es active Active
- 2011-04-01 JP JP2013501620A patent/JP5925759B2/ja active Active
- 2011-04-01 BR BR112012025092-2A patent/BR112012025092B1/pt active IP Right Grant
- 2011-04-01 CA CA2794930A patent/CA2794930C/en active Active
- 2011-04-01 RU RU2012146542/10A patent/RU2593948C2/ru active
- 2011-04-01 MX MX2012011424A patent/MX2012011424A/es unknown
- 2011-04-01 CN CN201180023063.3A patent/CN102884075B/zh active Active
- 2011-04-01 KR KR1020127028726A patent/KR101869917B1/ko active IP Right Grant
- 2011-04-01 US US13/637,845 patent/US9205128B2/en active Active
- 2011-04-01 AU AU2011235369A patent/AU2011235369B2/en not_active Ceased
- 2011-04-01 MY MYPI2012700711A patent/MY161923A/en unknown
- 2011-04-01 EP EP11720370.3A patent/EP2554550B1/en active Active
-
2012
- 2012-10-16 ZA ZA2012/07761A patent/ZA201207761B/en unknown
-
2015
- 2015-11-17 US US14/943,096 patent/US20160106810A1/en not_active Abandoned
- 2015-11-17 US US14/943,089 patent/US20160129073A1/en not_active Abandoned
- 2015-11-17 US US14/943,106 patent/US10434137B2/en active Active
-
2016
- 2016-02-03 JP JP2016019305A patent/JP6230635B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018006116A (es) | Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias. | |
WO2014197568A3 (en) | Rna-guideded transcriptional regulation | |
AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
HK1204568A1 (en) | Cosmetic product or skin regeneration promoter comprising nonhuman stem cell culture supernatant as starting material, and method for ion introduction for protein | |
WO2016061232A3 (en) | Multiplexed shrnas and uses thereof | |
WO2012135621A3 (en) | Priming of pluripotent stem cells for neural differentiation | |
WO2014028493A3 (en) | Exosomes and micro-ribonucleic acids for tissue regeneration | |
WO2013039861A3 (en) | Engineered nucleic acids and methods of use thereof | |
WO2011120474A8 (es) | Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos | |
EP2582795A4 (en) | METHOD FOR SELECTING HUMAN INDUCED PLURIPOTENT STEM CELLS | |
NZ761006A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
WO2012062810A3 (en) | Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor | |
AU2016255474A8 (en) | Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease | |
WO2013036850A3 (en) | Modulation of midbody derivatives | |
MX2015014892A (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
EP3489351A4 (en) | CELL CULTIVATION METHOD, SUSPENDED CELL ELIMINATION METHOD AND METHOD FOR KILLING SUSPENDED CELLS | |
EA201590088A1 (ru) | Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета | |
EP4282975A3 (en) | Methods for controlling fucosylation levels in proteins | |
HK1157814A1 (en) | Materials and methods relating to cell based therapies | |
WO2012102527A3 (ko) | 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도 | |
EP3279318A4 (en) | Human serum albumin-containing culture medium for growth of neural stem cells | |
WO2012135842A3 (en) | A unique population of regulatory t cells that regulate tissue regeneration and wound healing | |
MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180023063.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11720370 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2794930 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013501620 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201005178 Country of ref document: TH Ref document number: MX/A/2012/011424 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2011720370 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011720370 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2452/MUMNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011235369 Country of ref document: AU Date of ref document: 20110401 Kind code of ref document: A Ref document number: 2012146542 Country of ref document: RU Kind code of ref document: A Ref document number: 20127028726 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13637845 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012025092 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012025092 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121001 |